Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis.
AUTOR(ES)
Grayson, M L
RESUMO
To assess the potential efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) against serious enterococcal infections, we used a rat enterococcal endocarditis model comparing TMP-SMX therapy (500 mg of TMP plus 2,500 mg of SMX per kg of body weight per day given every 8 h by intragastric gavage) with intravenous ampicillin therapy (1,000 mg/kg per day). Despite concentrations of active drug in serum well in excess of the MIC and MBC, the mean residual vegetation bacterial titer in TMP-SMX-treated rats was similar to that in untreated controls (8.4 +/- 1.1 versus 8.6 +/- 1.3 log10 CFU/g) and significantly higher than that in the ampicillin-treated group (3.6 +/- 1.5 log10 CFU/g; P less than or equal to 0.001). This demonstrates discordance between in vitro activity and in vivo efficacy of TMP-SMX in serious enterococcal infection.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171927Documentos Relacionados
- Trimethoprim-sulfamethoxazole therapy of experimental Escherichia coli meningitis in rabbits.
- Successful Treatment of Pseudomonas cepacia Endocarditis with Trimethoprim-Sulfamethoxazole
- Trimethoprim-Sulfamethoxazole in Murine Toxoplasmosis
- Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis.
- Ampicillin therapy of experimental enterococcal endocarditis.
